Ratings
0
Nobody has rated this yet. Be the first!
Works
10
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
